The Phase III VALUE trial for EscharEx® is progressing, with an interim assessment and completion of enrollment anticipated by the end of the first quarter of 2027. This trial is a crucial stage in testing the effectiveness and safety of EscharEx®, with significant milestones expected to be reached in the near future. Stay tuned for updates on this important development in the medical field.